Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Chemotherapy Bill Needed To Ensure Reimbursement Covers Cost, ASCO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

American Society of Clinical Oncology interim measure would ensure oncologists’ Medicare Part B reimbursement for drugs cover acquisition costs. ASCO is collecting data to quantify losses to physicians due to payment changes made through Medicare Rx law.

You may also be interested in...



ASCO Targets Tax Bill For Reimbursement Changes; Goal Is Maintaining 2004 Payments

GOP leadership is "steadfastly opposed" to reopening any elements of Medicare law, ASCO Government Relations Council feels, but there is "some sympathy" for preventing steep cuts in 2005. ASCO position is not defending AWP, organization notes, but rather defending current levels of payments to physicians.

ASCO Targets Tax Bill For Reimbursement Changes; Goal Is Maintaining 2004 Payments

GOP leadership is "steadfastly opposed" to reopening any elements of Medicare law, ASCO Government Relations Council feels, but there is "some sympathy" for preventing steep cuts in 2005. ASCO position is not defending AWP, organization notes, but rather defending current levels of payments to physicians.

Roche's Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP

Centers for Medicare & Medicaid Services raises Xeloda's reimbursement rate from 85% of AWP based on data submitted by Roche. CMS also corrects payment allowance for the company's CellCept.

Related Content

Topics

UsernamePublicRestriction

Register

PS058630

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel